Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sanofi (Headquarters: Paris, France) and Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka) announced today that the two companies agreed to dissolve sanofi-aventis...
Read more about Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
Tokyo, February 20, 2012 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Sanwa Kagaku Kenkyusho Co., Ltd. (“SKK”; Headquarters: Nagoya;...
Astellas and UCB partner to bring certolizumab pegol to rheumatoid arthritis patients in Japan UCB files certolizumab pegol for marketing authorisation with the Japanese Ministry of Health, Labour...
Follow us
